Novavax, Inc. (NVAX)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Novavax, Inc. currently loses $94.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Next report — what to expect
Novavax, Inc. (NVAX) reports on November 5, 2026. Wall Street is looking for EPS of -$0.232 on revenue of $72.7 million. For trailing context, revenue fell -76.3% year over year last quarter. NVAX has beaten EPS in 7 of 8 most recent quarters, making upside/downside versus consensus a key focus.
About Novavax, Inc.
Novavax, Inc. develops and commercializes vaccines within the biotechnology sector, centered on preventing serious infectious diseases. The company trades on the NASDAQ Global Select Market under NVAX and generated $1.1 billion of revenue in FY2025, with its work spanning marketed and developing vaccine programs for several respiratory viruses.
Today's Snapshot
NVAX closed 2.9% below yesterday's close, in line with a weaker sector. Shares changed hands at about half of its usual level.
Trading Volume
Below 10d avg (7.8M)
4.4M
vs S&P 500 Today
Underperforming Market
-2.38%
Updated: October 23, 2026 at 20:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$9.21 - $11.08Sell
- RSI (14)40.33Neutral
- Stochastic %K (14, 3, 3)12.80Buy
- MACD Level (12, 26)0.10Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.